Kim Bobae 4
4 · Bellerophon Therapeutics, Inc. · Filed May 22, 2023
Insider Transaction Report
Form 4
Kim Bobae
VP Reg. Affairs & Quality
Transactions
- Exercise/Conversion
Common Stock
2023-05-18$7.35/sh+266$1,955→ 1,723 total - Exercise/Conversion
Common Stock
2023-05-18$7.50/sh+1,022$7,665→ 1,723 total - Sale
Common Stock
2023-05-18$10.00/sh−9,455$94,550→ 1,723 total - Exercise/Conversion
Stock Options (Right to Buy)
2023-05-18−266→ 0 totalExercise: $7.35Exp: 2026-12-07→ Common Stock (266 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2023-05-18−1,022→ 144 totalExercise: $7.50Exp: 2029-09-26→ Common Stock (1,022 underlying)
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.26, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F2]The shares subject to this option are fully vested and exercisable.
- [F3]This option was granted on September 26, 2019. This option vests in quarterly installments over a four-year period from the date of grant.